Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

No abstract is available for this paper.

• Publication year

  1965

• Venue

  New England Journal of Medicine

• Publication date

  1965-12-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM196512302732701PMID 5852902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FURTHER EXPERIENCE IN USE OF HUMAN ANTIHAEMOPHILIC GLOBULIN (H.A.H.G.) FOR THE CONTROL OF BLEEDING AFTER DENTAL EXTRACTION IN HAEMOPHILIC PATIENTS: A REPORT TO THE MEDICAL RESEARCH COUNCIL'S WORKING PARTY ON HUMAN ANTIHAEOMOPHILIC GLOBULIN.

  1965cited by this paper
• Use of Antihemophilic Factor (Plasma Fraction I-0) during Correction of Knee-Joint Deformities in Hemophilia A

  1965cited by this paper
• USE OF ANTIHEMOPHILIC FACTOR (PLASMA FRACTION I-O) DURING CORRECTION OF KNEE-JOINT DEFORMITIES IN HEMOPHILIA A. REPORT OF THREE CASES INCLUDING ONE OSTEOTOMY.

  1965cited by this paper
• HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.

  1964cited by this paper
• An Assay for Antihaemophilic Factor (Factor VIII) with Some Considerations Affecting the Establishment of a Standard Reference Preparation

  1964cited by this paper
• High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin Precipitate

  1964cited by this paper
• The Fate of Prothrombin and Factors VIII, IX and X Transfused to Patients Deficient in these Factors

  1963cited by this paper
• A Simple Assay Method for Factor × (Stuart-Prower Factor).∗

  1962cited by this paper
• A simple, specific one-stage assay for plasma thromboplastin antecedent activity.

  1961cited by this paper
• A new assay for factor V (proaccelerin-accelerin) using Russell's viper venom.

  1960cited by this paper
• Observations on Plasma Banking and Transfusion Procedures for Haemophihc Patients using a Quantitative Assay for Antihaemophilic Globulin (AHG) *

  1959cited by this paper
• Assay of Plasma Antihaemophilic Globulin (AHG) *

  1959cited by this paper
• The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin.

  1951cited by this paper

• Why is the uptake of gene therapy in hemophilia less than expected?

  2025cites this paper
• Emerging Therapies in Hemophilia: Improving Equitable Access to Care

  2025cites this paper
• Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care

  2025cites this paper
• Program Genealogies: Adult Hemophilia Treatment Center at the University of Toronto, St. Michael’s Hospital

  2025cites this paper
• The past, present and future of blood plasma fractionation.

  2025cites this paper
• Effect of Water Bath versus Refrigerator Thaw on Cryoprecipitate Fibrinogen and Factor VIII Content Using a Pre-Pooled Plasma Experimental Approach

  2024cites this paper
• Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies

  2024cites this paper
• Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List.

  2024cites this paper
• Perioperative Management of Hemophilia Patients

  2024cites this paper
• Investigations on the Hemostatic Potential of Physiological Body Fluids

  2024cites this paper
• Joint health and pain in the changing hemophilia treatment landscape

  2024cites this paper
• Hemostats in the clinic

  2024cites this paper
• The Evolution of Hemophilia Pharmacological Treatments and Therapeutic Targets at the Turn of the Third Millennium

  2024cites this paper
• Hemostatic capability of ultrafiltrated fresh frozen plasma compared to cryoprecipitate

  2023cites this paper
• Historic and emerging trends in transfusion medicine: Maintaining relevance as a specialty

  2023cites this paper
• Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers.

  2023cites this paper
• Hemophilia treatment innovation: 50 years of progress and more to come.

  2023cites this paper
• Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey

  2023cites this paper
• Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

  2022cites this paper
• Impact of novel hemophilia therapies around the world

  2022cites this paper
• The legacy of haemophilia: Memories and reflections from three survivors

  2022cites this paper
• The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng

  2022cites this paper
• Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future

  2022cites this paper
• The More Recent History of Hemophilia Treatment.

  2022cites this paper
• Viral hepatitis in haemophilia: historical perspective and current management

  2021cites this paper
• Recent Advances in the Treatment of Hemophilia: A Review

  2021cites this paper
• A novel modified thaw‐siphon method for extracting cryoprecipitate: The Bokutoh‐siphon method

  2021cites this paper
• Preparation, Storage, and Characteristics of Whole Blood, Blood Components, and Plasma Derivatives

  2021cites this paper
• Blood Coagulation Products and Other Hemostatic Agents

  2021cites this paper
• The History of Blood Transfusion and Blood Management

  2021cites this paper
• BTT_A_252580 221..235

  2021cites this paper
• Dr Judith Graham Pool and the development of cryoprecipitate

  2021cites this paper
• Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review.

  2021cites this paper
• FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A

  2020cites this paper
• Factor VIII: the protein, cloning its gene, synthetic factor and now – 35 years later – gene therapy; what happened in between?

  2020cites this paper
• MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia.

  2020cites this paper
• Transitioning of Care from Pediatric to Adult Providers Among Hemophilia Patients

  2020influential citation
• The German Hemophilia Registry: Growing with Its Tasks

  2020cites this paper
• Клиническое использование криопреципитата

  2020cites this paper
• “Whatever Works”: Innovations in the Treatment of Hemophilia in the United States 1783–1950

  2020cites this paper
• Healthcare professionals in the ‘tainted blood’ era in Canada: Their forgotten emotions

  2019cites this paper
• Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems

  2019cites this paper
• Influence of canine donor plasma hemostatic protein concentration on quality of cryoprecipitate

  2018cites this paper
• Do we still need cryoprecipitate? Cryoprecipitate and fibrinogen concentrate as treatments for major hemorrhage — how do they compare?

  2018cites this paper
• A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies

  2018cites this paper
• Factor VIII manufactured from plasma—the ups and downs, and the up again: a personal journey—part 1: history of the development of plasma-derived factor VIII therapies

  2018cites this paper
• Efficacy, Reliability, and Safety of Completely Autologous Fibrin Glue in Neurosurgical Procedures: Single-Center Retrospective Large-Number Case Study.

  2018cites this paper
• Preparation of Factor VIII Using an Ion Exchange Medium CaptoTM MMC

  2018cites this paper
• Purification of Factor VIII From Plasma by Q SepharoseTM Fast Flow Column

  2018cites this paper
• Purification of Factor VIII From Cryoprecipitation Using MacroCapTM Q Column

  2018cites this paper
• The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A

  2018cites this paper
• Management of Hemophilia in Older Patients

  2017cites this paper
• Production of recombinant coagulation factors: Are humans the best host cells?

  2017influential citation
• The dynamics of contract plasma fractionation.

  2017cites this paper
• Progress in the contemporary management of hemophilia: The new issue of patient aging.

  2017cites this paper
• The History of Clotting Factor Concentrates Pharmacokinetics

  2017cites this paper
• Factors influencing variation in blood product usage : an international perspective

  2017cites this paper
• The Current Global Status and Production Trends of Plasma Fractionation

  2017cites this paper
• Hemophilia in the 21st century: tremendous progress, tremendous opportunity.

  2016cites this paper
• Where now for transfusion: the evolution of a paradigm and its logical progression

  2016influential citation
• Detection and Prediction of Factor VIII Antibody Formation in Congenital and Acquired Haemophilia A

  2016cites this paper
• What Is Hemophilia

  2016cites this paper
• Evolution of Veterinary Transfusion Medicine and Blood Banking

  2016cites this paper
• Zmiany rodzaju koncentratu czynnika krzepnięcia u chorego na hemofilię – korzyść czy ryzyko?

  2016cites this paper
• The past and future of haemophilia: diagnosis, treatments, and its complications.

  2016cites this paper
• Gene therapy for hemophilia: past, present and future.

  2016cites this paper
• Inhibitor development in haemophilia according to concentrate

  2015cites this paper
• The long and short of it: using the new factor products.

  2015cites this paper
• Some Important Milestones in the Field of Blood Clotting

  2015cites this paper
• The Current Role of Bone Marrow Transplantation in the Treatment of Hemophilia A

  2014cites this paper
• Haemophilia, Past and Present

  2014cites this paper
• The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness

  2014cites this paper
• The history of haemophilia - a short review.

  2014cites this paper
• HEMOPHILIA-INHERITED BLEEDING DISORDER: AN OVERVIEW

  2014cites this paper
• The History of Hemophilia

  2014cites this paper
• Development of novel treatment options for patients with haemophilia

  2013cites this paper
• Diagnóstico y seguimiento de las lesiones musculoesqueléticas en el paciente hemofílico mediante ecografía: comparación con los resultados de resonancia magnética

  2013cites this paper
• A brief review of 50 years of perioperative thrombosis and hemostasis management.

  2013cites this paper
• Entwicklung neuer Behandlungsoptionen für Hämophilie-Patienten

  2013cites this paper
• The plasma wars: a history

  2012cites this paper
• Native analysis of plasma‐derived clotting factor VIII concentrates: “Sponge effect” and contaminants

  2012cites this paper
• The Clinical Indications for Cryoprecipitate Use A Critical Review

  2012cites this paper
• Blood Products for Hemophilia

  2012cites this paper
• Development and introduction of recombinant factor VIII – a clinician’s experience

  2012cites this paper
• Judith Graham Pool and the discovery of cryoprecipitate

  2012cites this paper
• Plasma-derived medicines: access and usage issues.

  2012cites this paper
• Clinical Communications: Adults ROLE OF NON-OPERATIVE MANAGEMENT OF SPLEEN INJURY IN PATIENTS WITH HEMOPHILIA: REPORT OF TWO PATIENTS WITH REVIEW OF LITERATURE

  2011cites this paper
• syndrome Antibody-induced von Willebrand's disease: a newly defined inhibitor

  2011cites this paper
• Role of non-operative management of spleen injury in patients with hemophilia: report of two patients with review of literature.

  2011cites this paper
• ACCESS AND RATIONAL USE OF PLASMA PROTEIN THERAPIES (PPTS)

  2011cites this paper
• A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A

  2011cites this paper
• Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

  2011cites this paper
• Historical perspective and future direction of coagulation research

  2011cites this paper
• Falsification or paradigm shift? Toward a revision of the common sense of transfusion

  2011cites this paper
• Plasma‐derived clotting factor VIII: Heterogeneity evaluation in the quest for potential inhibitory‐antibody stimulating factors

  2011cites this paper
• Storage of whole blood for up to 24 hours at ambient temperature before component preparation: implementation in the Netherlands

  2011cites this paper
• Factor VIII safety: plasma-derived versus recombinant products.

  2011cites this paper
• Joint Health, Functional Ability and Physical Activity in Haemophilia

  2011cites this paper
• STUDIES ON THE PREPARATIONS OF ANTIHEMOPHILIC FACTOR (F.VIII)

  2010cites this paper
• A critical evaluation of cryoprecipitate for replacement of fibrinogen

  2010cites this paper